Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
229.7 CHF +1.30% Intraday chart for Roche Holding AG +2.07% -6.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: Apple, UBS, Microstrategy, Merck, Amazon... Our Logo
Roche's Chugai Wins Japanese Approval for Piasky Injection MT
Roche Obtains US FDA Approval for Cobas Malaria Test MT
Roche Gets FDA Approval for Malaria Screen Test DJ
Roche: FDA green light for 'cobas' test CF
Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors CI
ROCHE HOLDINGS AG : Deutsche Bank reiterates its Sell rating ZD
ROCHE HOLDINGS AG : Gets a Sell rating from Deutsche Bank ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from UBS ZD
Luxury stocks drag European equities lower ahead of Fed meeting RE
Roche: sale of Genentech plant for $1.2 billion CF
Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Billion DJ
Lonza to Buy US Biologics Manufacturing Site from Roche for $1.2 Billion MT
Lonza to buy biologics site from Roche in US for $1.2 bln RE
Lonza to acquire biologics site from Roche in U.S. for $1.2 billion RE
Lonza Group AG entered into an agreement to acquire Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG for $1.2 billion. CI
Roche: AGM approves dividend increase CF
ROCHE HOLDINGS AG : Sell rating from Deutsche Bank ZD
ROCHE HOLDINGS AG : Barclays remains Neutral ZD
Swiss Market Index Edges Up; Consumer Sentiment Falls MT
Transcript : Roche Holding AG - Special Call
Why do family businesses outperform? Our Logo
Roche, Alnylam's Zilebesiran Meets Primary Endpoint in Mid-stage Trial for Mild, Moderate Hypertension MT
Roche: positive phase II data in hypertension CF
Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension CI
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
226.8 CHF
Average target price
281.3 CHF
Spread / Average Target
+24.05%
Consensus
  1. Stock
  2. Equities
  3. Stock Roche Holding AG - Swiss Exchange
  4. News Roche Holding AG
  5. Roche Gets EU's Nod For Vabysmo in Treatment of Two Vision Loss Diseases